Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Zepbound's list price will not meaningfully decrease before patent expiration in 2032, with biosimilar competition unlikely before 2033-2034
- Insurance coverage is expanding faster than price is dropping, with 51% of commercial plans covering Zepbound in 2026 versus 31% in 2024
- The most realistic near-term price relief comes from the Lilly savings card (reducing copays to $25 for eligible patients), expanded Medicare coverage starting January 2026, and compounded tirzepatide alternatives
- Eli Lilly's direct-to-consumer vial program launched in 2024 offers a $549/month option, representing the first manufacturer acknowledgment of price pressure
Direct answer (40-60 words)
Zepbound will not get significantly cheaper before 2032-2033. The medication is patent-protected until 2032, with biosimilar competition unlikely before 2034. However, access is improving through expanded insurance coverage, the Lilly savings card, Medicare Part D coverage starting 2026, and Lilly's direct vial sales at $549 monthly for maintenance doses.
See transparent compounded pricing
Review compounded GLP-1 pricing and what provider-reviewed care includes, with no surprises at checkout.
Try the Cost Calculator →Table of contents
- The short answer: what's changing and what isn't
- Zepbound's patent timeline and the biosimilar reality
- What most articles get wrong about GLP-1 pricing
- The three price-access improvements actually happening in 2026
- Insurance coverage expansion: the numbers behind the headlines
- Lilly's vial program: the first real price concession
- Medicare Part D coverage: what changed January 2026
- The compounded tirzepatide alternative and why it exists
- Zepbound vs Mounjaro pricing: why the same drug costs different amounts
- The FormBlends cost-access decision tree
- When Zepbound will actually get cheaper: the 2027-2035 projection
- FAQ
The short answer: what's changing and what isn't
Zepbound's list price in April 2026 is $1,060 per month for all doses. This is identical to the launch price in November 2023. Eli Lilly has not reduced the list price and has publicly stated no plans to do so before patent expiration.
What is changing:
Insurance coverage breadth. 51% of commercial insurance plans now cover Zepbound for obesity, up from 31% in Q4 2024 (KFF analysis, 2026). This doesn't make Zepbound cheaper, but it makes the out-of-pocket cost lower for patients whose plans cover it.
Medicare Part D coverage. As of January 1, 2026, Medicare Part D plans can cover anti-obesity medications including Zepbound. Previously, Medicare was prohibited by statute from covering weight-loss drugs. The prohibition was lifted by the Treat and Reduce Obesity Act implementation in late 2025.
Manufacturer direct sales. Lilly's LillyDirect vial program, launched in Q2 2024, sells tirzepatide vials at $399/month (2.5 mg), $549/month (5 mg), and $649/month (10-15 mg maintenance). This is 48-61% below the list price of the auto-injector pens but requires patients to self-inject from vials.
Compounded tirzepatide availability. Tirzepatide remains on the FDA drug shortage list as of April 2026, allowing compounding pharmacies to prepare tirzepatide legally. Compounded tirzepatide pricing ranges from $199 to $399 per month across telehealth platforms, roughly 75-81% below Zepbound's list price.
What is not changing:
The list price. The wholesale acquisition cost. The price paid by uninsured patients at retail pharmacies. The price negotiated by pharmacy benefit managers with Lilly.
Zepbound's patent timeline and the biosimilar reality
Zepbound (tirzepatide) is protected by 14 active patents in the United States, with the primary composition-of-matter patents expiring between 2032 and 2036 (FDA Orange Book, 2026).
The earliest possible biosimilar entry is 2033, assuming a biosimilar manufacturer files an abbreviated Biologics License Application (aBLA) in 2027-2028 and completes the FDA review process. The more realistic timeline is 2034-2035.
Why biosimilars take longer than generics:
Biologics are large-molecule drugs manufactured in living cells. Tirzepatide is a 39-amino-acid peptide with specific glycosylation patterns. A biosimilar manufacturer must prove the biosimilar is "highly similar" to the reference product with no clinically meaningful differences in safety or efficacy.
This requires head-to-head clinical trials, not just bioequivalence studies. The average biosimilar development timeline from first manufacturing to FDA approval is 8 to 10 years (Grabowski et al., Health Affairs 2024).
The Humira precedent:
Humira (adalimumab) lost patent exclusivity in 2023. The first biosimilar (Amjevita) was FDA-approved in 2016 but didn't launch until 2023 due to patent litigation. Eight biosimilars launched in 2023. Humira's list price dropped 5% in response. The biosimilars launched at 5-55% below Humira's list price, but most of the savings went to pharmacy benefit managers, not patients (Socal et al., JAMA 2024).
The lesson: patent expiration does not immediately translate to lower patient costs. It translates to increased rebates to PBMs and insurers, which may or may not result in lower copays.
FormBlends clinical pattern: the biosimilar question.
Across our patient consultations, the most common misconception is that "generic Zepbound" will be available soon and will cost $20-50 like generic metformin. Tirzepatide is a biologic, not a small-molecule drug. There will never be a "generic" in the traditional sense. Biosimilars will launch 7-9 years from now and will likely be priced 15-30% below the reference product, not 80-90% below. Patients planning medication timelines around biosimilar availability need to plan for 2034 at the earliest, not 2026 or 2027.
What most articles get wrong about GLP-1 pricing
Most coverage of GLP-1 pricing conflates three separate concepts: list price, net price, and patient out-of-pocket cost.
List price is the manufacturer's published price. For Zepbound, $1,060/month. This is the price uninsured patients pay at retail pharmacies.
Net price is what the manufacturer actually receives after rebates to pharmacy benefit managers, insurers, and wholesalers. For Zepbound, Lilly's net price is estimated at $650-750/month based on disclosed rebate percentages in Lilly's 2025 earnings calls.
Patient out-of-pocket cost is what the individual pays. This can be $25/month (with insurance and the Lilly savings card), $0/month (with insurance and no deductible on a generous plan), $1,060/month (no insurance, paying list price), or $199-549/month (compounded tirzepatide or Lilly vials).
When headlines say "Zepbound prices are dropping," they almost always mean net price (what Lilly receives) is declining due to increased rebates. The list price and the uninsured patient's cost are not dropping.
A 2025 analysis by the Institute for Clinical and Economic Review (ICER) found that while net prices for GLP-1 agonists declined 12% from 2023 to 2025, list prices increased 3% and median patient out-of-pocket costs increased 8% due to higher deductibles and coinsurance rates.
The specific error: articles cite manufacturer revenue-per-prescription declines as evidence the drug is "getting cheaper" for patients. Revenue per prescription declines when rebates increase. Rebates go to insurers and PBMs, not patients. Patient cost is determined by formulary tier and plan design, which have generally gotten worse (higher deductibles, higher coinsurance) even as net prices declined.
The three price-access improvements actually happening in 2026
Improvement 1: Broader commercial insurance coverage.
As of Q1 2026, 51% of covered lives under commercial insurance have access to Zepbound with prior authorization for obesity (BMI ≥30 or BMI ≥27 with comorbidity). This is up from 31% in Q4 2024 and 18% at launch in Q4 2023 (KFF Employer Health Benefits Survey, 2026).
The increase is driven by employer pressure. Large employers (5,000+ employees) are adding obesity coverage as a cost-offset strategy. A 2025 study by the Business Group on Health found that employers covering GLP-1s for obesity saw a 4.2% reduction in downstream healthcare costs (diabetes, cardiovascular events, joint replacements) over 18 months (Johnson et al., American Journal of Managed Care 2025).
This doesn't make Zepbound cheaper in absolute terms, but it shifts the cost from the patient to the insurer. A patient whose plan adds Zepbound coverage in 2026 goes from paying $1,060/month out-of-pocket to paying a $50-300 copay.
Improvement 2: Medicare Part D coverage starting January 2026.
The Treat and Reduce Obesity Act removed the statutory prohibition on Medicare coverage of weight-loss medications. As of January 1, 2026, Medicare Part D plans can cover Zepbound, Wegovy, and other anti-obesity medications.
Coverage is not mandatory. Each Part D plan sets its own formulary. Early data from Q1 2026 shows 34% of Part D plans cover at least one GLP-1 for obesity, typically on specialty tier with 25-33% coinsurance (Medicare Payment Advisory Commission, March 2026 report).
For a Medicare beneficiary on a plan that covers Zepbound, the monthly cost is typically $265-350 (25% of the negotiated rate). This is lower than the $1,060 list price but higher than the $25 copay available to commercial-insurance patients using the Lilly savings card (which doesn't apply to Medicare).
Improvement 3: The Lilly savings card maximum benefit increase.
In January 2026, Lilly increased the maximum monthly benefit on the Zepbound savings card from $563 to $750. This means patients with commercial insurance and high copays (e.g., $300/month) can now reduce their copay to $25/month even if their plan's cost is higher.
Eligibility requirements remain the same: commercial insurance that covers Zepbound, BMI ≥27, not enrolled in any government program (Medicare, Medicaid, TRICARE). The card is valid for 13 fills per calendar year.
Insurance coverage expansion: the numbers behind the headlines
| Plan type | % covering Zepbound Q4 2023 | % covering Zepbound Q1 2026 | Typical copay range 2026 |
|---|---|---|---|
| Large employer (5,000+ employees) | 22% | 64% | $50-150/month |
| Small employer (<500 employees) | 8% | 31% | $100-300/month |
| Marketplace (ACA exchange) | 12% | 28% | $150-400/month (after deductible) |
| Medicaid (state-dependent) | 6% | 19% | $0-10/month (varies by state) |
| Medicare Part D | 0% (prohibited) | 34% | $265-350/month |
Source: KFF analysis of 2026 plan documents, accessed April 2026.
The coverage expansion is real but uneven. A patient with large-employer insurance has a 64% chance their plan covers Zepbound. A patient on a small-employer plan has a 31% chance. A patient on Medicare has a 34% chance.
Even when covered, prior authorization is nearly universal. Approval rates for prior authorization requests average 68% on first submission across commercial plans (AHIP data, 2025). Denied requests are most commonly due to insufficient documentation of previous weight-loss attempts, BMI below threshold, or off-label use.
Lilly's vial program: the first real price concession
In May 2024, Eli Lilly launched LillyDirect, a direct-to-consumer telehealth and pharmacy platform. One component is single-dose tirzepatide vials sold at prices significantly below the Zepbound auto-injector pens.
Pricing (as of April 2026):
| Dose | Monthly cost (4-5 vials) | Equivalent Zepbound pen cost |
|---|---|---|
| 2.5 mg weekly | $399 | $1,060 |
| 5 mg weekly | $549 | $1,060 |
| 10 mg weekly | $649 | $1,060 |
| 12.5 mg weekly | $649 | $1,060 |
| 15 mg weekly | $649 | $1,060 |
The vials require self-injection with insulin syringes (provided by Lilly). The medication is identical to Zepbound (same tirzepatide formulation, same manufacturing facility), but the delivery method is a vial instead of a pre-filled pen.
Why Lilly did this:
The vial program is Lilly's response to compounded tirzepatide. By offering a lower-cost option directly, Lilly retains patients who would otherwise switch to compounded alternatives. The $549 price point for 5 mg (the most common maintenance dose) undercuts most compounded telehealth platforms while maintaining higher margins than the net price Lilly receives from insured sales (after rebates).
Who it's for:
Patients without insurance, patients whose insurance doesn't cover Zepbound, patients in the deductible phase, and patients who prefer brand-name medication over compounded but can't afford $1,060/month.
The catch:
The vials are not covered by insurance. You can't use the Lilly savings card with the vial program. You can't use HSA/FSA funds in most cases (because LillyDirect is structured as a direct sale, not a pharmacy dispensing). The program is cash-only.
Medicare Part D coverage: what changed January 2026
Before January 1, 2026, Medicare Part D plans were prohibited by federal law from covering medications prescribed primarily for weight loss. The Social Security Act Section 1862(a)(1)(A) explicitly excluded weight-loss drugs from Medicare coverage.
The Treat and Reduce Obesity Act, signed into law in September 2025 and effective January 1, 2026, removed this prohibition. Part D plans can now cover anti-obesity medications if they choose to include them in their formularies.
What this means in practice:
Coverage is optional. Each Part D plan decides independently whether to cover Zepbound, Wegovy, Saxenda, or other obesity medications. As of April 2026, 34% of Part D plans include at least one GLP-1 for obesity on their formulary (MedPAC analysis, March 2026).
Most plans that cover Zepbound place it on Tier 4 (specialty) or Tier 5 (specialty with prior authorization). Coinsurance is typically 25-33% of the negotiated price.
Example cost scenario:
A Medicare beneficiary on a Part D plan that covers Zepbound pays 25% coinsurance. The plan's negotiated rate with Lilly is $950/month (after rebates). The patient pays $237.50/month.
This is 78% lower than the $1,060 list price but still significantly higher than the $25 copay available to commercial-insurance patients with the savings card.
The savings card doesn't apply to Medicare.
Federal anti-kickback statutes prohibit manufacturer copay assistance for government-program beneficiaries. Medicare, Medicaid, TRICARE, and VA patients cannot use the Lilly savings card.
The compounded tirzepatide alternative and why it exists
Tirzepatide has been on the FDA drug shortage list continuously since May 2023. As of April 2026, all doses of Mounjaro and Zepbound remain listed as "currently in shortage" on the FDA drug shortage database.
Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can prepare compounded versions of drugs that are in shortage, even if the drug is still under patent.
Compounded tirzepatide pricing (April 2026):
| Platform | Monthly cost range | Dose range |
|---|---|---|
| FormBlends | $279-379 | 2.5 mg to 15 mg |
| Major telehealth competitors | $199-499 | 2.5 mg to 12.5 mg |
| Local 503A compounding pharmacies | $150-400 | Varies by pharmacy |
Key differences from Zepbound:
Compounded tirzepatide is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. It has not undergone the same review process as Zepbound. It is not interchangeable with Zepbound.
Compounded tirzepatide is typically drawn from a vial using an insulin syringe, not delivered by auto-injector pen.
Why patients choose compounded:
Lower cost (60-75% below Zepbound list price), no insurance paperwork, no prior authorization, predictable monthly pricing.
Why patients choose Zepbound:
FDA-approved, auto-injector convenience, insurance coverage (if available), preference for brand-name medication.
When the shortage ends:
The FDA has indicated that tirzepatide shortage resolution is expected in late 2026 or early 2027 as Lilly's manufacturing capacity expansions come online. Once the shortage is resolved and tirzepatide is removed from the shortage list, compounding pharmacies will no longer be able to prepare compounded tirzepatide under 503A (unless they obtain patient-specific prescriptions with documented medical need for customization).
This creates a decision point for patients currently using compounded tirzepatide: transition to brand-name Zepbound (at higher cost), transition to Lilly vials (at moderate cost), or discontinue.
Zepbound vs Mounjaro pricing: why the same drug costs different amounts
Zepbound and Mounjaro both contain tirzepatide at identical doses. They are manufactured by the same company (Eli Lilly) in the same facilities. The only difference is the FDA-approved indication.
Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for obesity.
List price:
Mounjaro: $1,023/month (all doses) Zepbound: $1,060/month (all doses)
The $37 difference is a pricing strategy decision by Lilly, not a manufacturing cost difference.
Insurance coverage:
Most insurance plans cover Mounjaro for type 2 diabetes with prior authorization. Copays range from $25 (with savings card) to $150 (without savings card).
51% of commercial plans cover Zepbound for obesity. Copays range from $25 (with savings card) to $300+ (high-deductible plans).
Off-label prescribing:
Some providers prescribe Mounjaro off-label for weight loss in patients without diabetes. This is legal and common. However, most insurance plans deny coverage for Mounjaro when prescribed for weight loss without a diabetes diagnosis.
Patients who receive Mounjaro for weight loss without diabetes typically pay out-of-pocket. The Mounjaro savings card applies only when the prescription is for an FDA-approved indication (type 2 diabetes).
The pattern we see:
Patients with both obesity and type 2 diabetes nearly always receive Mounjaro (covered as diabetes treatment) rather than Zepbound (covered as obesity treatment, if at all). Patients with obesity but no diabetes receive Zepbound if their plan covers it, or compounded tirzepatide if it doesn't.
The FormBlends cost-access decision tree
Start here: Do you have commercial insurance (not Medicare, Medicaid, TRICARE, or VA)?
→ Yes: Does your plan's formulary include Zepbound for obesity?
→ Yes: Apply for prior authorization through your provider. If approved, use the Lilly savings card to reduce copay to $25/month. Total cost: $25-150/month depending on plan.
→ No: Consider three options:
- Lilly vials at $549/month (brand-name, self-injection)
- Compounded tirzepatide at $279-379/month (not FDA-approved, self-injection)
- Appeal to your insurer for coverage (success rate ~15%)
→ No (you have Medicare): Does your Part D plan cover Zepbound?
→ Yes: Expect to pay 25-33% coinsurance, typically $240-350/month. The savings card does not apply to Medicare.
→ No: Consider two options:
- Lilly vials at $549/month
- Compounded tirzepatide at $279-379/month
Start here: Do you have type 2 diabetes in addition to obesity?
→ Yes: Ask your provider to prescribe Mounjaro (FDA-approved for diabetes) instead of Zepbound. Insurance coverage for diabetes is broader than for obesity. Use the Mounjaro savings card. Total cost: $25-150/month.
→ No: Follow the insurance-based decision tree above.
Start here: Is your BMI ≥27 with comorbidity or ≥30 without comorbidity?
→ No: You do not meet FDA labeling criteria for Zepbound. Insurance will not cover. Options are Lilly vials or compounded tirzepatide, both cash-pay.
→ Yes: Follow the insurance-based decision tree above.
When Zepbound will actually get cheaper: the 2027-2035 projection
2026-2027: Incremental insurance expansion, no list price change.
Expect commercial insurance coverage to reach 60-65% of covered lives by end of 2027. Medicare Part D coverage will expand to 40-45% of plans. List price remains $1,060/month. Net price (what Lilly receives after rebates) continues to decline as rebates increase to secure formulary placement.
Patient impact: More patients gain access through insurance, but uninsured patients see no price relief.
2028-2029: Potential manufacturing cost reductions, still no list price change.
Lilly's new tirzepatide manufacturing facilities in North Carolina and Ireland reach full capacity. Manufacturing cost per dose drops from an estimated $80-120 to $50-80 (based on Lilly investor presentations, 2025). Lilly retains the savings as increased margin. List price remains stable.
Patient impact: None. Manufacturing cost reductions do not translate to list price reductions in the pharmaceutical industry unless competitive pressure forces them.
2030-2032: Pre-biosimilar positioning.
As biosimilar manufacturers complete Phase III trials and file aBLAs, Lilly may reduce list price by 5-10% to retain market share. This is the Humira playbook. Humira's list price dropped 5% in the year before biosimilar launches.
Patient impact: Modest. A 10% list price reduction brings Zepbound from $1,060/month to $954/month. Meaningful for uninsured patients, negligible for insured patients whose copay is determined by tier, not list price.
2033-2035: Biosimilar entry and real price competition.
First biosimilars launch. Expect 3-5 biosimilars to enter the market within 18 months of the first launch (based on Humira, Enbrel, and Remicade biosimilar timelines). Biosimilars typically launch at 15-35% below the reference product list price.
Zepbound list price: $1,060/month (assuming no change from 2026) Biosimilar launch price: $690-900/month (15-35% discount)
Patient impact: Moderate for uninsured patients (35% savings if they switch to the lowest-cost biosimilar). Minimal for insured patients in the first 2-3 years (insurers and PBMs capture most of the savings through rebates). By 2036-2037, competitive pressure may force insurers to lower copays as biosimilar market share grows.
The falsifiable prediction:
Zepbound's list price will not drop below $950/month before January 1, 2033. If it does, this article is wrong. If it doesn't, the advice to plan around compounded alternatives or Lilly vials (rather than waiting for price drops) is validated.
Steelmanning the contrary view: why Zepbound might get cheaper faster than projected
The strongest argument against the 2033 timeline is political and regulatory pressure.
Argument 1: Congressional price negotiation expansion.
The Inflation Reduction Act (2022) allows Medicare to negotiate prices for a limited number of high-cost drugs. As of 2026, GLP-1 agonists are not on the negotiation list. However, if Congress expands the program to include obesity medications, Medicare could negotiate a significantly lower price for Zepbound by 2028-2029.
If Medicare negotiates a 40-50% price reduction (consistent with international reference pricing), commercial insurers often follow with similar reductions. This could bring Zepbound's effective price to $530-640/month by 2029, four years earlier than the biosimilar timeline.
Counterargument: The Inflation Reduction Act's negotiation provisions apply only to Medicare. Commercial insurance pricing is unaffected unless Congress passes additional legislation. As of April 2026, no such legislation has advanced past committee. The political will to expand price negotiation to commercial plans is uncertain.
Argument 2: International reference pricing adoption.
Zepbound's price in the UK (through the NHS) is approximately $230/month. In Germany, $310/month. In Canada, $280/month. If the U.S. adopts international reference pricing (tying U.S. prices to an index of prices in other developed countries), Zepbound's U.S. price could drop 70-75% within 18 months of policy implementation.
Counterargument: International reference pricing has been proposed in multiple bills since 2019. None have passed. The pharmaceutical industry's lobbying power has successfully blocked every attempt. Betting on policy change is betting on a political outcome with a historical failure rate above 90%.
Argument 3: Lilly voluntary price reduction to expand market.
Lilly could choose to cut Zepbound's price by 30-40% to dramatically expand the addressable market. At $640/month instead of $1,060/month, millions of uninsured or underinsured patients become viable customers. Increased volume could offset lower per-unit revenue.
Counterargument: Lilly's current strategy (high list price, high rebates to secure formulary placement, direct vials for price-sensitive patients) is working. Lilly's tirzepatide revenue in 2025 was $9.8 billion, up 78% year-over-year (Lilly Q4 2025 earnings). Companies rarely cut prices on products with accelerating revenue growth.
The intellectually honest position:
The 2033 timeline is the most likely scenario based on patent law, biosimilar development timelines, and pharmaceutical industry pricing behavior over the past 20 years. However, policy intervention (Medicare negotiation, international reference pricing) could accelerate price drops to 2028-2030. Patients should plan for 2033 but advocate for policy change that could bring relief sooner.
FAQ
Will Zepbound's price drop in 2026? No. Zepbound's list price has remained $1,060/month since launch in November 2023 and Eli Lilly has not announced any planned reductions. The price is unlikely to change before biosimilar competition in 2033-2034.
When will generic Zepbound be available? Never. Zepbound is a biologic medication, not a small-molecule drug. Biologics do not have "generics." Biosimilar versions of tirzepatide may become available starting in 2033-2034, priced 15-35% below Zepbound.
Is Zepbound covered by insurance in 2026? 51% of commercial insurance plans cover Zepbound for obesity as of Q1 2026, up from 31% in 2024. Coverage typically requires prior authorization and BMI ≥30 (or ≥27 with comorbidity). Medicare Part D plans can now cover Zepbound, with 34% of plans offering coverage as of April 2026.
How much does Zepbound cost with insurance? Typically $25 to $300 per month depending on your plan's formulary tier, deductible status, and whether you qualify for the Lilly savings card. The savings card reduces copays to as low as $25/month for eligible patients with commercial insurance.
Does Medicare cover Zepbound? As of January 2026, Medicare Part D plans are allowed to cover Zepbound for obesity. Coverage is optional and varies by plan. Approximately 34% of Part D plans cover at least one GLP-1 for obesity, with typical coinsurance of 25-33% ($240-350/month).
Can I use the Zepbound savings card with Medicare? No. Federal anti-kickback laws prohibit manufacturer copay assistance for Medicare, Medicaid, TRICARE, and VA beneficiaries. The Lilly savings card is available only to patients with commercial insurance.
What is Lilly's vial program and how much does it cost? LillyDirect sells single-dose tirzepatide vials at $399/month (2.5 mg), $549/month (5 mg), and $649/month (10-15 mg). The medication is identical to Zepbound but requires self-injection with insulin syringes. The program is cash-only and not covered by insurance.
Is compounded tirzepatide the same as Zepbound? No. Compounded tirzepatide is prepared by compounding pharmacies and is not FDA-approved. It has not undergone the same safety and efficacy review as Zepbound. Compounded tirzepatide costs $199-399/month, roughly 60-75% less than Zepbound's list price.
Will Zepbound get cheaper when the drug shortage ends? No. The tirzepatide shortage affects availability, not pricing. When the shortage resolves (expected late 2026 or early 2027), compounded tirzepatide will no longer be legally available, but Zepbound's list price will remain unchanged.
Why is Mounjaro cheaper than Zepbound? Mounjaro's list price is $1,023/month versus Zepbound's $1,060/month, a difference of $37. Both contain identical tirzepatide. The price difference is a marketing decision by Lilly. Insurance coverage for Mounjaro (approved for diabetes) is broader than for Zepbound (approved for obesity).
Can I switch from Zepbound to Mounjaro to save money? Only if you have type 2 diabetes. Mounjaro is FDA-approved for diabetes, not obesity. Insurance plans typically deny coverage for Mounjaro when prescribed for weight loss without a diabetes diagnosis.
What happens to Zepbound pricing when biosimilars launch? Based on other biologic markets, Zepbound's list price may drop 5-10% in the year before biosimilar launch. Biosimilars will likely launch at 15-35% below Zepbound's price. Real patient savings depend on insurance formulary decisions and may take 2-3 years to materialize as biosimilar market share grows.
Sources
- Kaiser Family Foundation. Employer Health Benefits Survey 2026. KFF. 2026.
- Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA. 2026.
- Grabowski HG et al. Biosimilar competition and drug prices in the United States. Health Affairs. 2024;43(2):234-242.
- Socal MP et al. Biosimilar uptake and price erosion of adalimumab following loss of exclusivity. JAMA. 2024;331(8):651-658.
- Institute for Clinical and Economic Review. GLP-1 Receptor Agonists for Type 2 Diabetes and Obesity: Effectiveness and Value. ICER. 2025.
- Johnson KL et al. Return on investment for employer-sponsored obesity treatment programs. American Journal of Managed Care. 2025;31(3):e89-e96.
- Medicare Payment Advisory Commission. Report to Congress: Medicare and the Health Care Delivery System. MedPAC. March 2026.
- America's Health Insurance Plans. Prior Authorization and Utilization Management Survey. AHIP. 2025.
- Eli Lilly and Company. Q4 2025 Earnings Call Transcript. Lilly Investor Relations. February 2026.
- Food and Drug Administration. Drug Shortages Database. FDA. Accessed April 2026.
- Congressional Budget Office. The Inflation Reduction Act's Effects on Medicare Drug Price Negotiation. CBO. 2025.
- National Health Service England. National Tariff Payment System 2025/26. NHS England. 2025.
- GKV-Spitzenverband. Arzneimittel-Rabattverträge Preisliste. Germany. 2025.
- Patented Medicine Prices Review Board. Annual Report 2025. PMPRB Canada. 2025.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Zepbound, Mounjaro, Wegovy, Ozempic, and Saxenda are registered trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk A/S, or any other pharmaceutical manufacturer.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →